Lithuania vs Trinidad and Tobago: Hepatitis B surface antigen (HBsAg) prevalence
Lithuania
0.1%
in 2024
Trinidad and Tobago
0.1%
in 2024
Lithuania rank
101st
Trinidad and Tobago rank
101st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Lithuania
- Trinidad and Tobago
How they compare
Lithuania currently reports 0.1% against 0.1% in Trinidad and Tobago, a difference of 0.0%.
Across all 10 years both countries report, Trinidad and Tobago has been ahead every year.
Lithuania ranks 101st and Trinidad and Tobago ranks 101st of 194 countries.
Trinidad and Tobago has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lithuania | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.2% | 0.1% | Trinidad and Tobago |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Lithuania or Trinidad and Tobago?
- Lithuania, at 0.1% against 0.1% in Trinidad and Tobago as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Lithuania and Trinidad and Tobago?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Trinidad and Tobago?
- 10 years are reported by both, from 2015 to 2024.
- How do Lithuania and Trinidad and Tobago rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Lithuania ranks 101st and Trinidad and Tobago ranks 101st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.